Modeling of pharmacokinetics of ganciclovir

Not Applicable

Recruiting

• Conditions: cytomegalovirus infection; Infection - Other infectious diseases

• Registration Number: ACTRN12622000645752
• Lead Sponsor: Motol University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-05-03
• Last Update Posted: 10 April 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

had undergone lung transplantation and treated with intravenous ganciclovir twice daily for at least 48 hours after transplantation

Exclusion Criteria

incomplete date

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
estimating ganciclovir AUC in lung transplant patients using NONMEN<br>Pharmacokinetics of ganciclovir assessed using blood samples. The pharmacokinetic parameter of interest is AUC<br>valganciclovir is prodrug of ganciclovir<br>[<br>5 minutes prior dosing and 2,4,6 hours post dose]

Secondary Outcome Measures

Name	Time	Method
pharmacokinetics parameter - serum assay<br> the parameters to be examined, . ganciclovir Cmax, ganciclovir Tmax, ganciclovir T1/2, AUC<br>pharmacokinetics of ganciclovir in blood sample<br>[<br>5 minutes prior to dosing and 2,4,6 hours post dose]